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The United Kingdom Health Protection Agency
Mycobacterium Reference Unit offers a national “Fastrack”
molecular service for detecting Mycobacterium tuberculo-
sis complex (MTBC) and rifampin resistance by using the
INNO-LiPA Rif.TB assay. We analyzed the service in a rou-
tine, nontrial context of 1,997 primary clinical specimens,
including 658 nonrespiratory specimens. The overall
adjusted concordance, sensitivity, specificity, positive pre-
dictive value, and negative predictive value for detecting
MTBC were 91.2%, 85.2%, 96.2%, 95.7%, and 86.7%,
respectively (unadjusted, 86.7%, 85.2%, 88.2%, 86.9%,
and 86.7%), when false-positive samples from patients (n =
83) with a known microbiologic diagnosis of MTBC or
patients receiving current or recent antituberculous treat-
ment were excluded. The parameters for detecting rifampin
resistance were 99.1%, 95.0%, 99.6%, 92.7%, and 99.7%,
respectively. The assay enabled earlier diagnosis of MTBC
and rifampin resistance (15.2 days) compared with culture-
based techniques (30.7 days).
T
he increasing incidence of multidrug-resistant tubercu-
losis (MDRTB), defined as resistance to at least
rifampin and isoniazid, is a notable global health problem
(1). The rapid identification of patients with MDRTB
enables early institution of appropriate treatment, which is
associated with improved survival (2,3), and infection con-
trol procedures to minimize risk of transmission (4). The
Centers for Disease Control and Prevention recommends
that the culture/identification and susceptibility testing of
Mycobacterium tuberculosis complex (MTBC) be complet-
ed within 21 and 30 days of specimen receipt, respectively
(5). Molecular assays based on the genetics of drug resist-
ance may considerably reduce these turnaround times. 
In the United Kingdom, 82.5% of rifampin-resistant
isolates are also resistant to isoniazid (6), making rifampin
resistance a useful surrogate marker for MDRTB. Most
rifampin-resistant MTBC strains have mutations in an 81-
bp region of the rpoB gene that encodes the RNA poly-
merase  β subunit (7). This region is therefore an ideal
target for molecular tests for rifampin resistance. 
The United Kingdom Health Protection Agency
Mycobacterium Reference Unit (MRU) offers a national
molecular diagnostic service (Fastrack) for detection of
MTBC and rifampin resistance (8) by using the INNO-
LiPA Rif.TB assay (Innogenetics, Zwijndrecht, Belgium)
and supplemented by DNA sequencing as needed. This
assay is based on reverse hybridization between rpoB
amplicons and membrane-bound capture probes (1 specif-
ic for MTBC, 5 overlapping wild-type probes spanning the
rpoB target region, and 4 of the most common mutations).
Genotypic resistance is indicated by absence of hybridiza-
tion with wild-type probes or hybridization with resistance
mutation probes (9).
Areview of the line probe assay (LiPA) (10) found that
most previous evaluations focused on mycobacterial iso-
lates and culture-positive (mainly respiratory) specimens
(9,11–14), but relatively little data exist on nonrespiratory
and smear-negative specimens, which are often collected
in routine clinical practice (8,15,16). The Fastrack service
was initially targeted at smear-positive respiratory samples
and mycobacterial isolates, but in response to widespread
demand from other laboratories, was extended to all spec-
imens, regardless of acid-fast bacilli (AFB) status. In
January 2002, an in-house polymerase chain reaction
(PCR) assay targeting the IS6110 insertion sequence (17)
replaced LiPA for testing cerebrospinal fluid (CSF) sam-
ples. Therefore, CSF samples were not included in this
study. This study evaluated LiPAin the context of a nontri-
al clinical service in one of the largest reported samples of
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Materials and Methods
Clinical Specimens 
From January 1999 through December 2002, the MRU
received 2,287 consecutive non-CSF specimens from
2,110 patients (comprising 1,997 primary clinical speci-
mens and 290 clinical isolates) from 152 centers in the
United Kingdom and Ireland for Fastrack analysis.
Specimens are submitted for analysis at the discretion of
individual referring laboratories, usually when the diagno-
sis of MTBC is uncertain or when rifampin resistance is
suspected. When multiple specimens were received from a
single patient, each specimen was processed separately. Of
the primary specimens, 1,339 respiratory specimens were
sputum, bronchial washings, and bronchial and tracheal
aspirates; 658 were nonrespiratory specimens. Samples
were received only on weekdays, and routine processing
and culture were initiated within 24 hours of receipt.
Turnaround times for completion of analysis, culture, and
identification of MTBC and drug-susceptibility testing
were calculated from date of specimen receipt (5). 
Routine Microscopy, Culture, Identification, 
and Susceptibility Testing 
Samples were decontaminated by using the NaOH/N-
acetyl-L-cysteine method in a 2-mL suspension, and AFB
staining was performed with auramine-phenol and the
Ziehl-Neelsen procedure (18,19). DNAwas extracted from
1 mL of decontaminated specimen by using a previously
described chloroform extraction technique (20), and the
remaining 1 mL was added to 1 MB/BacT rapid culture
vial (bioMérieux UK Ltd., Basingstoke, UK) and 1
Lowenstein-Jensen slope. Cultures were incubated for at
least 8 weeks. Mycobacterial cultures were identified by
microscopic and macroscopic appearances, biochemical
tests, and DNA hybridization with Accuprobe (GenProbe,
San Diego, CA, USA). Drug-susceptibility testing was car-
ried out by the resistance ratio method (18).
LiPA
LiPA was performed according to manufacturer’s
instructions. The first round of a nested PCR was per-
formed with 10 µL of DNA extract and outer primers
(LiPA OP1, 5′-GAGAATTCGGTCGGCGAGCTGATCC-
3′ and LiPA OP2, 5′-CGAAGCTTGACCCGCGCGTA-
CACC-3′) for 30 cycles at 95°C for 60 s, 58ºC for 30 s, and
72ºC for 90 s. One microliter of first-round product was
transferred to a 40-µL PCR mixture containing inner
primers (LiPAIP1, 5′-GGTCGGCATGTCGCGGATGG-3′
and LiPA IP2, 5′-GCACGTCGCGGACCTCCAGC-3′),
which were biotinylated at the 5′ end, for the second round
of amplification for 30 cycles at 95°C for 20 s, 65ºC for 30
s, and 72°C for 30 s. Each PCR run included a duplicate
and an inhibition control (100 genome copies of
Mycobacterium bovis bacillus Calmette-Guérin [BCG])
for each sample, 5 extracted, water, negative controls,
decontaminated, extracted, negative and positive controls
(a known culture-positive clinical sample), and a positive
control with a low amount of DNA (10 genome copies of
BCG in 10 µL). A 260-bp band on agarose gel elec-
trophoresis confirmed successful amplification. The
hybridization assay to determine genotypic rifampin resist-
ance was then performed and analyzed as previously
described (13). The MTBC result was then reported as pos-
itive (accompanied by a rifampin-susceptibility result),
negative, equivocal, or inhibited. Results were considered
equivocal if a sample tested PCR positive on 1 of 2 dupli-
cates on 2 separate occasions. Extracted DNA was stored
for retesting equivocal and inhibited results and for future
resolution of discrepant susceptibility results.
Sequencing of rpoB PCR Product 
Cultures of MTBC with discordant rifampin-suscepti-
bility results by phenotypic and LiPA testing underwent
automated sequencing of the rpoB PCR products with
either the Long Read Tower System (Visible Genetics,
Suwanee, GA, USA) or the CEQ 8000 Genetic Analysis
System (Beckman Coulter, High Wycombe, UK). DNA
was extracted from cultures and amplified in a PCR con-
taining the outer primers OP1 and OP2 and sequenced with
the inner primers IP1 and IP2. 
Statistical Analysis 
Data were entered into Microsoft Access (Microsoft
Corp., Redmond, WA, USA) and analyzed with Microsoft
Excel. Detection of MTBC and rifampin resistance by LiPA
was compared with results by the accepted standards of cul-
ture and phenotypic susceptibility testing. Concordance,
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated. We
excluded 85 (3.7%) samples from primary analysis because
LiPA results could not be compared with culture results.
These samples had equivocal PCR results (n = 27, 1.2%),
were inhibitory to PCR (n = 22, 1.0%), could not be cul-
tured (e.g., because of insufficient volume or histologic
samples embedded in paraffin wax; n = 6, 0.3%), or were
contaminated with bacteria or fungi (n = 30, 1.3%).
Results
Microscopy and Culture 
Of the primary specimens tested by LiPA, the AFB
smear microscopy was positive in 1,137 (56.9%), negative
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types are shown in Tables 1 and 2. Culture identification
and drug susceptibility results are shown in Table 3.
MTBC was cultured from 941 (47.1%) of 1,997 primary
samples and 238 (82.1%) of 290 isolates. In 3 cases, both
MTBC and nontuberculous mycobacteria were cultured. A
total of 1,178 M. tuberculosis, 10 M. bovis (including 1
BCG), and 1 M. africanum cultures were identified in the
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of tuberculosis were reported in the United Kingdom per
year, including 4,500–5,000 reported to be culture positive
(6). The times taken to culture MTBC from primary spec-
imens are shown in Table 4. There were 223 nontubercu-
lous mycobacteria isolates: 80 M. avium complex, 38 M.
kansasii, 26 M. xenopi, 23 M. malmoense, 20 M. chelonae,
10 M. fortuitum, 3 M. abscessus, 3 M. marinum, 2 M. gor-
donae, 2 M. simiae, 2 M. terrae, 1 M. szulgai, 1 M. vaccae,
and 12 unidentified Mycobacterium species. 
LiPA
Results of LiPA analysis for MTBC were positive in
1,153 (50.4%), negative in 1,085 (47.4%), equivocal in 27
(1.2%), and inhibited in 22 (1.0%) primary specimens. Of
the 1,153 PCR-positive samples, 1,085 (94.1%) were
reported as rifampin susceptible by LiPA, and 68 (5.9%)
were reported as rifampin resistant. Of the 27 PCR-equiv-
ocal samples, 16 grew MTBC (6 AFB negative, 1 AFB
unknown, 9 AFB positive), 3 grew M. avium complex, and
8 yielded no mycobacterial growth. Tables 1 and 2, respec-
tively, show the results of LiPA in detecting MTBC from
primary specimens and rifampin resistance from speci-
mens that grew MTBC. Data on antituberculous treatment
were incomplete, but when reported, 195 (9.8%) samples
were from patients receiving treatment currently or within
the last 3 months. A total of 309 (15.5%) had a history of
antituberculous treatment (Tables 5 and 6).
Discrepant Results
There were 136 false-negative MTBC results, i.e., sam-
ples negative by LiPA that subsequently yielded MTBC on
culture. There were 118 apparently false-positive MTBC
results by LiPA, which were PCR positive but did not grow
MTBC, although 88 were AFB positive. Atotal of 83 false-
positive samples were considered to have correct molecular
results because they were from patients with a microbiolog-
ic diagnosis of MTBC made at MRU from another sample
(n = 61) or from patients who were receiving antitubercu-
lous treatment currently or had received it within the last 3
months (n = 22). These 83 samples were excluded from sta-
tistical analysis to give adjusted values for specificity and
PPV (Table 1). Ten specimens were from 6 patients with
discrepant results for rifampin susceptibility (Table 7).
M. tuberculosis and Rifampin Resistance, United Kingdom
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 5, May 2006 755Eight specimens had wild-type rpoB, and 2 had mutations
not associated with rifampin resistance.
Discussion
We assessed LiPA on the largest reported sample of
1,997 clinical specimens in a nontrial, routine context that
would be meaningful to clinicians, especially those sub-
mitting samples other than AFB-positive respiratory spec-
imens. The overall unadjusted concordance, sensitivity,
specificity, PPV, and NPV were 86.7%, 85.2%, 88.2%,
86.9%, and 86.7%, respectively, for detecting MTBC in
primary samples and 98.9%, 98.7%, 100%, 100%, and
93.3%, respectively, for isolates. Previous studies that test-
ed mainly respiratory samples and isolates reported con-
cordance rates with culture from 78.3% to 100% and were
usually controlled studies (8–16).
When PCR was compared with culture for detecting
MTBC, some false-positive results may, in fact, have been
true-positive results. Of 118 samples classified as false
positive, 83 were believed to be true positive on the basis
of our planned protocol. These consisted of 61 samples
from patients with a microbiologic diagnosis of MTBC at
our laboratory in the last 18 or subsequent 3 months and an
additional 22 samples from patients who were receiving
antituberculous treatment or who had received it within the
last 3 months. Patients who were receiving treatment cur-
rently or within the last 3 months were significantly less
likely to have MTBC; of 195 samples from such patients,
70 (35.9%) had MTBC compared to 871 (49.3%) of 1,766
samples from patients with no reported treatment within
the last 3 months (χ2 = 12.7, p<0.001). Furthermore, a sig-
nificantly higher proportion of rifampin-resistant MTBC
was isolated from patients receiving treatment (12/70,
17.1%) compared with patients not reported to be receiv-
ing treatment (34/866, 3.9%, χ2 = 24.2, p<0.001). In these
83 false-positive samples believed to represent true posi-
tive results, PCR detected nucleic acid from nonviable
organisms (due to treatment) or viable organisms in insuf-
ficient numbers for successful culture. If these 83 samples
are excluded from overall analysis, specificity improves
for all primary specimens, AFB-positive specimens, and
AFB-negative specimens from 88.2%, 70.8%, and 95.7%,
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97.7% (Table 1). PPV improves from 86.9%, 89.5% and
54.7%, respectively, to 95.7%, 97.5% and 70.0%. Other
false-positive samples could probably be excluded; we
only chose to exclude those with microbiologic diagnoses
of MTBC at our laboratory because we had no data on
microbiologic, histologic, or clinical diagnoses made by
the other hospitals that submitted these samples.
Furthermore, since relevant data were often not provided,
many more patients likely were receiving antituberculous
therapy that we were unaware of because treatment failure
is a common reason for specimens being submitted for
testing. 
PCR-equivocal results were excluded from the primary
analysis. However, a PCR-equivocal result may represent
a lack of sensitivity. If PCR-equivocal results are consid-
ered PCR negative, the adjusted values for detecting
MTBC in primary specimens were only marginally altered
to 90.6%, 84.0%, 96.2%, 95.7%, and 85.7%, respectively,
for concordance, sensitivity, specificity, PPV, and NPV.
A recent review of LiPA results reported that although
little data on clinical specimens were available, sensitivity
appeared lower than that of isolates (10). Our study con-
firmed this finding, with sensitivities of 85.2% for all clin-
ical specimens and 98.7% for isolates. As with other
PCR-based tests (21–23), sensitivities of LiPA for AFB-
negative (29.4%) and nonrespiratory samples (61.1%)
were low. Sensitivity was also reduced to 71.6% in patients
receiving treatment at the time or within 3 months of the
time the sample was obtained. Marttila et al. tested 75 clin-
ical specimens with LiPA, including 66 from nonrespirato-
ry sites, and reported a sensitivity of 58.8% compared with
final clinical and pathologic diagnoses, whereas cultures
showed a sensitivity of 35.3% (15). Several factors may
explain the lower sensitivity of PCR-based methods in
these samples. The mycobacterial load is lower, as demon-
strated by the significantly shorter time taken to culture
MTBC for AFB-positive samples than for AFB-negative
samples (18.5 days vs. 29.5 days, z = 8.0, p<0.001), and
respiratory samples than nonrespiratory samples (18.7
days vs. 25.0 days, z = 5.6, p<0.001). However, more res-
piratory samples were AFB positive (94.3% vs. 55.0%).
Irregular clumping may take place within paucibacillary
specimens, and small, suboptimal sample volumes often
lead to sampling errors. Nonrespiratory specimens, espe-
cially pleural fluid, bone marrow, pus, and tissue biopsy
specimens, may contain inhibitors of amplification
(22,23). Inhibition rates in this study were 1.0% overall,
with above-average rates in blood and feces (both 2/3,
[66.7%]), pleural fluid (2/110 [1.8%]), bone marrow (1/23
[4.3%]), and pus/tissue (8/400 [2.0%]).
The nonrespiratory specimen types with the highest
sensitivity rates were vertebral aspiratesbiopsy specimens
(n = 30, sensitivity 83.3%), gastric aspirates (n = 18, sen-
sitivity 80.0%), and lymph node aspirates/biopsy speci-
mens (n = 144, sensitivity 72.5%). For pleural fluid, one of
the most commonly submitted samples (n = 107), LiPA
had one of the lowest sensitivity rates (21.7%) for detect-
ing MTBC. The difficulties in detecting MTBC in pleural
fluid are well recognized, with previous reported sensitiv-
ities of 20% (24) and 50% (23) with the Gen-Probe ampli-
fied M. tuberculosis direct test.
For detecting rifampin resistance in PCR-positive spec-
imens yielding MTBC on culture, LiPA had concordance,
sensitivity, specificity, PPV, and NPV values of 99.1%,
95.0%, 99.6%, 92.7%, and 99.7%, respectively. These
results are consistent with previous studies that reported
concordance rates of 90.2% to 100% (8–18). In this study,
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PCR negative for MTBC. Of the remaining 64 that were
PCR positive, 59 (93.7%) had detectable rpoB mutations
and were reported as resistant. At least 90% of rifampin-
resistant strains have mutations within the target rpoB
region, although this proportion may vary in different pop-
ulations (7).
Detection of rifampin resistance by LiPA may be used
as an early predictor of MDRTB before phenotypic suscep-
tibilities are available, but this clearly depends on the
prevalence of rifampin monoresistance in the study popu-
lation. The diagnosis of rifampin monoresistance is also
critical because this automatically invalidates the use of
short-course chemotherapy (25). Of the 59 correctly iden-
tified rifampin-resistant MTBC isolates, 11 were rifampin
monoresistant. The overall prevalence was 1.0% in this
study, which was higher than the 0.3% reported in a
national UK survey (6). This result reflects a common
underlying reason for specimen referral for Fastrack analy-
sis, i.e., failure of response to treatment.
For primary samples in which LiPA detected MTBC,
diagnosis of tuberculosis was made an average of 15.2
days earlier than with automated liquid culture (14.8 days
for AFB-positive specimens and 22.1 days for AFB-nega-
tive specimens). More days were saved with nonrespirato-
ry samples (18.3 days) than with respiratory samples (14.7
days), although these samples had the lowest probability of
detection. LiPA accurately determined rifampin suscepti-
bility earlier than solid culture-based techniques by a mean
of 30.7 days for all primary specimens. This compares
favorably with a study that found that LiPA saved a medi-
an of 24 days compared with susceptibility testing with the
BACTEC liquid culture system (Becton Dickinson,
Sparks, MD, USA) and 54 days with solid media (11).
In summary, LiPA may be used with clinical samples
for diagnosis of MTBC and rifampin resistance, saving,
when positive results are obtained, an average of 15.2 days
and 30.7 days, respectively, compared with conventional
techniques. However, some limitations of LiPA are evi-
dent. As with other PCR-based assays, sensitivity is
reduced in AFB-negative and nonrespiratory samples, such
as paucibacillary forms of the disease, in which rapid diag-
nosis would be most helpful. Although the assay is a
potential diagnostic route for patients receiving therapy,
sensitivity is also reduced in these circumstances. The
lower sensitivity rates for certain samples and the possibil-
ity of a PCR-equivocal or PCR-inhibited result also mean
that conventional culture and sensitivity testing should still
be used at the same time. Alternatives to LiPAmay be use-
ful, e.g., we used an IS6110-based PCR for diagnosis of
tuberculous meningitis. Similarly, rifampin-resistance
mutations can be detected by DNA sequencing (we now
sequence all PCR products identified as MTBC with any
form of rifampin probe mutations) or with noncommercial
macroarrays (26,27). Thus, molecular results, as with any
laboratory test, should be reviewed in the context of all
clinical, microbiologic, and histologic results.
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